
CureVac B.V (CVAC) Stock Forecast & Price Target
CureVac B.V (CVAC) Analyst Ratings
Bulls say
CureVac NV is strategically positioned within the competitive mRNA landscape, capitalizing on the high value generated by COVID-19 vaccines and the anticipated broader applications of mRNA technology. The company has established a significant collaboration with GSK, focusing on developing advanced vaccine candidates for seasonal and avian influenza, alongside oncology and molecular therapies targeting various diseases. Additionally, the advancement of its development programs demonstrates a commitment to innovation, reinforcing the positive outlook for CureVac's future growth and potential market success.
Bears say
CureVac NV is expected to continue incurring net losses until at least product approval and commercialization, potentially extending into the early launch phase. The company faces significant competitive risks as it may struggle to compete effectively against established and in-development candidates in the mRNA vaccine space. Furthermore, legal and intellectual property risks could further exacerbate revenue generation challenges, potentially impacting future sales significantly.
This aggregate rating is based on analysts' research of CureVac B.V and is not a guaranteed prediction by Public.com or investment advice.
CureVac B.V (CVAC) Analyst Forecast & Price Prediction
Start investing in CureVac B.V (CVAC)
Order type
Buy in
Order amount
Est. shares
0 shares